Key Points
- CFO Alexandra Balcom sold 11,430 shares on April 1 at an average price of $105.21 for a total of $1,202,550.30, reducing her position by 11.79% to 85,533 shares (≈$8.999M).
- Balcom also sold shares earlier in January (4,236 and 3,181 shares), totaling approximately $721,313 across those two transactions.
- Nuvalent trades around $105 with a market cap of $8.29B and a 12‑month range of $55.53–$113.01, and analysts hold a consensus "Moderate Buy" with an average target of $137.25 (16 Buys, 1 Sell).
Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) CFO Alexandra Balcom sold 11,430 shares of the company's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $105.21, for a total transaction of $1,202,550.30. Following the completion of the sale, the chief financial officer owned 85,533 shares of the company's stock, valued at approximately $8,998,926.93. This trade represents a 11.79% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Alexandra Balcom also recently made the following trade(s):
- On Tuesday, January 6th, Alexandra Balcom sold 3,181 shares of Nuvalent stock. The stock was sold at an average price of $97.16, for a total transaction of $309,065.96.
- On Monday, January 5th, Alexandra Balcom sold 4,236 shares of Nuvalent stock. The shares were sold at an average price of $97.32, for a total transaction of $412,247.52.
Nuvalent Price Performance
NUVL opened at $105.43 on Friday. The firm has a market capitalization of $8.29 billion, a P/E ratio of -18.02 and a beta of 1.31. The stock has a fifty day moving average of $101.43 and a 200-day moving average of $98.96. Nuvalent, Inc. has a 12-month low of $55.53 and a 12-month high of $113.01.
Analysts Set New Price Targets
Several brokerages recently issued reports on NUVL. Cantor Fitzgerald increased their price objective on Nuvalent from $135.00 to $140.00 and gave the stock an "overweight" rating in a research note on Friday, February 27th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nuvalent in a report on Thursday, January 22nd. Wells Fargo & Company began coverage on shares of Nuvalent in a research report on Monday, March 30th. They issued an "overweight" rating and a $116.00 price target for the company. JPMorgan Chase & Co. lowered their price objective on shares of Nuvalent from $147.00 to $145.00 and set an "overweight" rating on the stock in a research report on Friday, December 19th. Finally, UBS Group reiterated a "buy" rating on shares of Nuvalent in a research note on Wednesday, December 17th. Sixteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $137.25.
Read Our Latest Stock Report on Nuvalent
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of NUVL. GAMMA Investing LLC increased its position in Nuvalent by 47.6% in the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company's stock worth $34,000 after purchasing an additional 108 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of Nuvalent during the 3rd quarter valued at about $38,000. Eastern Bank bought a new stake in shares of Nuvalent in the 3rd quarter valued at approximately $52,000. NBC Securities Inc. acquired a new position in Nuvalent in the fourth quarter worth approximately $125,000. Finally, KBC Group NV raised its position in Nuvalent by 24.1% during the fourth quarter. KBC Group NV now owns 1,527 shares of the company's stock valued at $154,000 after acquiring an additional 297 shares in the last quarter. Hedge funds and other institutional investors own 97.26% of the company's stock.
Nuvalent Company Profile
(
Get Free Report)
Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company's research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.
Nuvalent's lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
